Amarin's Vascepa misses primary endpoint in Phase 3 colorectal cancer trial

By Public Technologies
  • Amarin reported Phase 3 EMT2 results showing VAZKEPA/VASCEPA missed its primary goal of delaying cancer progression but improved overall survival.
  • The University of Leeds-sponsored trial evaluated adjunctive treatment in colorectal cancer patients undergoing surgery for liver metastases.
  • Results were presented at the European Society for Medical Oncology 2026 Congress in Madrid.
  • Treatment was well tolerated, with no excess adverse events or meaningful deterioration in quality of life versus placebo.
  • The findings support further evaluation of the cardiovascular drug’s potential use in cancer care.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610250811PRIMZONEFULLFEED9852658) on October 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.